Chinook Therapeutics, Inc (KDNY)

Etorro trading 970x250
Chinook Therapeutics, Inc (KDNY) Logo

About Chinook Therapeutics, Inc

Chinook Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of precision medicines for kidney diseases. The company’s lead clinical program is atrasentan, an investigational Phase III ready endothelin receptor antagonist for the treatment of IgA nephropathy and other primary glomerular diseases. Its product candidates include BION-1301, an investigational anti-APRIL monoclonal antibody is being evaluated in a Phase Ib trial for IgA nephropathy; and CHK-336, a preclinical development candidate for an undisclosed ultra-orphan kidney disease, as well as research programs for other rare, severe chronic kidney diseases, including polycystic kidney disease. Chinook Therapeutics, Inc. is based in Seattle, Washington. Address: 1600 Fairview Avenue East, Seattle, WA, United States, 98102

Chinook Therapeutics, Inc News and around…

Latest news about Chinook Therapeutics, Inc (KDNY) common stock and company :

Week In Review: BeiGene Raises $3.5 Billion In Shanghai STAR Board IPO
04 Dec, 2021 FinancialContent

Beijing's BeiGene announced its Shanghai STAR Exchange IPO will raise $3.5 billion in gross proceeds for the company, more than the predictions of $3 billion. It is the third listing for the company, following Nasdaq and Hong Kong IPOs.

SanReno, a China JV, Formed with $40 Million and Two Kidney Disease Drugs
01 Dec, 2021 FinancialContent

SanReno Therapeutics, a China joint venture, was formed by Chinook Therapeutics (NSDQ: KDNY) and an investor syndicate led by Frazier Healthcare Partners and Pivotal bioVenture Partners China. The syndicate invested $40 million for a 50% stake in the JV, while Chinook contributed two kidney disease precision medicines for the other 50%. Chinook develops novel kidney candidates via its single cell RNA sequencing, human-derived organoids and new translational models. SanReno has exclusive rights to Chinook's atrasentan and BION-1301 in Greater China. More details.... Share this with colleagues:

Chinook Therapeutics Announces Formation of SanReno Therapeutics, a Joint Venture to Develop Kidney Disease Therapies in China
30 Nov, 2021 Yahoo! Finance

50/50 joint venture with investor syndicate led by Frazier Healthcare Partners and Pivotal bioVenture Partners ChinaExpands global reach and execution for Chinook’s atrasentan and BION-1301 programs in IgA nephropathy (IgAN) SEATTLE , Nov. 30, 2021 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (Nasdaq: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, today announced the formation of SanReno Therapeutics, a

Strong Insider Buying Puts These 3 Stocks in Focus
23 Nov, 2021 Yahoo! Finance

Investors are always looking for the right signal, something that will indicate where a stock is likely to move. These can be positive or negative – what matters most is accuracy. The stock market is an expression of the collective will and opinions of millions of traders, investors, and corporate execs. The most successful stock players are those who learn to read what the signals are saying. One of the clearest signals comes from the corporate insiders. These company officers get an inside vie

Analysts See 74% Gains Ahead For The Holdings of LABU
18 Nov, 2021 FinancialContent

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the Daily S&P Biotech Bull 3X Shares ETF (LABU), we found that the implied analyst target price for the ETF based upon its underlying holdings is $87.81 per unit.

Chinook Therapeutics Announces Closing of $183.5 Million Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
15 Nov, 2021 Yahoo! Finance

SEATTLE, Nov. 15, 2021 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (Nasdaq: KDNY) today announced the closing of its upsized underwritten public offering of 9,538,572 shares of its common stock at a price to the public of $14.00 per share, which includes the exercise in full of the underwriters’ option to purchase an additional 1,710,000 shares of its common stock. In addition, and in lieu of common stock, Chinook offered to certain investors pre-funded warrants to purchase up to an aggregate

76 Biggest Movers From Yesterday
11 Nov, 2021 FinancialContent

Gainers Expensify, Inc. (NASDAQ: EXFY) jumped 52.1% to settle at $41.06 on Wednesday after the company priced its IPO at $27 per ...

Chinook Therapeutics Announces Pricing of an Upsized $160 Million Public Offering
10 Nov, 2021 Yahoo! Finance

SEATTLE, Nov. 09, 2021 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (Nasdaq: KDNY) today announced the pricing of its upsized underwritten public offering of 7,828,572 shares of its common stock at a price to the public of $14.00 per share. In addition, and in lieu of common stock, Chinook is offering to certain investors pre-funded warrants to purchase up to an aggregate of 3,571,428 shares of common stock at a purchase price of $13.9999 per pre-funded warrant, which represents the per share

The Daily Biotech Pulse: Double Dose Of Positive Tidings For Merck, Alkermes Slips On Partial Termination Of J&J Licensing Deal, Amgen Migraine Drug Data
09 Nov, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Merck Gets Antitrust Nod For ...

Chinook Therapeutics Announces Proposed Public Offering of Common Stock
08 Nov, 2021 Yahoo! Finance

SEATTLE, Nov. 08, 2021 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (Nasdaq: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, today announced that it intends to offer and sell 6,000,000 shares of its common stock in an underwritten public offering. In addition, Chinook intends to grant the underwriters a 30-day option to purchase up to an additional 900,000 shares of its common stock offered in the public

Interesting KDNY Put And Call Options For April 2022
08 Nov, 2021 FinancialContent

Investors in Chinook Therapeutics Inc (KDNY) saw new options become available this week, for the April 2022 expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 157 days until expiration the newly available contracts represent a possible opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration..

Chinook Therapeutics Provides Business Update and Reports Third Quarter 2021 Financial Results
08 Nov, 2021 Yahoo! Finance

SEATTLE, Nov. 08, 2021 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (Nasdaq: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, today provided a business update and reported financial results for the third quarter ended September 30, 2021. “During the third quarter of 2021, we focused on execution and advancement of our lead clinical programs, atrasentan and BION-1301 for IgA nephropathy, a serious progress

92 Biggest Movers From Friday
08 Nov, 2021 FinancialContent

Gainers Mainz Biomed B.V. (NASDAQ: MYNZ) shares jumped 99.8% to close at $9.99 on Friday. Mainz Biomed priced its initial public ...

Notable Friday Option Activity: GPRO, KDNY, EFX
05 Nov, 2021 FinancialContent

Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in GoPro Inc (GPRO), where a total of 28,949 contracts have traded so far, representing approximately 2.9 million underlying shares. That amounts to about 131.1% of GPRO's average daily trading volume over the past month of 2.2 million shares..

12 Health Care Stocks Moving In Friday's Intraday Session
05 Nov, 2021 FinancialContent

Gainers Chinook Therapeutics (NASDAQ:KDNY) shares increased by 28.75% to $15.76 during Friday's regular session. ...

64 Stocks Moving In Friday's Mid-Day Session
05 Nov, 2021 FinancialContent

Gainers Mainz Biomed B.V. (NASDAQ: MYNZ) shares climbed 198.4% to $14.92. Mainz Biomed priced its initial public offering of 2 ...

Chinook Therapeutics Presents Data from BION-1301 Phase 1/2 Trial in Patients with IgA Nephropathy (IgAN) and Atrasentan Program at the American Society of Nephrology (ASN) Kidney Week 2021
04 Nov, 2021 Yahoo! Finance

BION-1301 was well-tolerated and demonstrated rapid and sustained reductions in mechanistic biomarkers in patients with IgAN, including free APRIL, IgA and Gd-IgA1 levelsBION-1301 demonstrated >50% proteinuria reduction in patients with IgAN after three to six months of treatment, with further reductions in two patients through one year of treatmentAdditional data was presented on the atrasentan program, including translational research demonstrating ETA activation is associated with clinical pr

The Daily Biotech Pulse: Merck's Oral COVID-19 Pill Authorized In UK, Novartis Cashes Out Of Roche, Chimerix Plunges On Data, Evotec IPO
04 Nov, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Merck's Oral Antiviral ...

The Week Ahead In Biotech (Oct. 31-Nov. 6): Earnings Pick Up Pace, Eton Awaits Seizure Drug Approval, Kidney Conference, More IPOs In The Pipeline
31 Oct, 2021 FinancialContent

Biotech stocks rose a third week running in the week ending Oct. 29 amid positive reaction to earnings. Big pharma earnings were mostly ...

Chinook Therapeutics Enters Oversold Territory (KDNY)
20 Oct, 2021 FinancialContent

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100..

Chinook Therapeutics Announces Upcoming Data Presentations and Investor Conference Call During the American Society of Nephrology (ASN) Kidney Week 2021
15 Oct, 2021 Yahoo! Finance

Additional data to be presented from the ongoing phase 1/2 study of BION-1301 in patients with IgA nephropathy, including biomarker and proteinuria reductions Several presentations on the atrasentan clinical program, including translational research demonstrating ETA activation is associated with clinical progression in IgA nephropathy Chinook to host investor conference call and webcast on November 4, 2021 to review abstracts and provide updates on the company’s pipeline SEATTLE, Oct. 15, 2021

Investors in Chinook Therapeutics (NASDAQ:KDNY) have unfortunately lost 15% over the last year
06 Oct, 2021 Yahoo! Finance

Investors can approximate the average market return by buying an index fund. But if you buy individual stocks, you can...

Chinook Therapeutics to Present at Upcoming Investor Conferences
20 Sep, 2021 FinancialContent
Insiders Go Big on These 3 Hot Stocks
25 Aug, 2021 Yahoo! Finance

Summer’s going fast, and it’s time to consider one of the stock market’s peculiarities: we’re apt to see a bump in the fall, as seasonal vacations end. This year, that seasonal bump will coincide with a reopened economy – assuming, of course, that there are no new lockdowns due to COVID. We can’t see into the future, but there are signals we can look for that may give some insight into where a particular stock is going. One clear signal comes from corporate insiders, the officers whose positions

The Past Week's Notable Insider Buys Include AppLovin, Cricut, Biotechs, And More
21 Aug, 2021 FinancialContent

With earnings-reporting season all but over, many insiders are free once more to buy or sell shares. Here are a few of the most noteworthy insider purchases that were reported in the past week.

The Past Week's Notable Insider Buys Included AppLovin, Cricut, Biotechs And More
21 Aug, 2021 FinancialContent

Insider buying can be an encouraging signal for potential investors, especially when markets are near all-time highs. Some ...

Chinook Therapeutics Provides Business Update and Reports Second Quarter 2021 Financial Results
12 Aug, 2021 FinancialContent
Analysts Anticipate LABU Will Reach $97
05 Aug, 2021 FinancialContent

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the Daily S&P Biotech Bull 3X Shares ETF (LABU), we found that the implied analyst target price for the ETF based upon its underlying holdings is $96.81 per unit.

Oversold Conditions For Chinook Therapeutics
26 Jul, 2021 FinancialContent

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100..

Chinook Therapeutics to Present at the William Blair Biotech Focus Conference 2021
12 Jul, 2021 FinancialContent

Chinook Therapeutics, Inc (KDNY) is a NASDAQ Common Stock listed in , ,

970x250